Member Info for Soupdragon78

Oh ok, so there is no chance of something happening, but you're here because you think there may be a chance of the thing you say can't happen happening?

Then why are you here?

The %age is somewhat irrelevant as the royalty is capped at £2m anyway.

So even at a 10% level, the royalty would hit its cap of Oxilio achieved low sales of only £20m. Nfx wouldn’t get anymore of the sales subsequently rose to £200m, hence the %age isn’t much concern.

Unfortunately we don't know the %age, so difficult to determine when the 2m figure might be achieved.

Hence, my view is that it would be better to sell the asset to fund toward NXP004.

Forgoing a possible £2m revenue in 7+ years time to outlicense something far bigger in the medium term makes sense to me.

Relax, that works as one hypothesis, but when are those royalties from sales achieved?

Likely the quickest to market for NXP001 would be 7 years from now (going by Oxilio's own information), then how long before they hit the required sales to get the royalty to £2m?

So, unless you are expecting NFX to still be £2m mcap in 7+ years then the royalties are inconsequential at the moment.

Well given that the ERS congress is only 7 weeks away the key is to complete the additional work to prove repeatability (a major factor in gaining interest), then to use the forum as a means of communicating this.

Theres no rush for a deal, the key is to get more than one horse in the race and build competition between them.

Relax, you do know that it wasn't Dan at the ERS last year don't you?

As Dan said on 13 June Q&A

'[we are]....just building out a Target list of companies that we want to take the NXP002 story to and that's a more specific longer term activity, building out the story, approaching companies with the right kind of message and establishing contacts, that's activities underway as well the European respiratory Congress meets this year in September in Milan we hope to have a a considerable number of discussions at that kind of event with obviously discussions already underway with a discrete number of specific partners'

Alternatively I think a deal to offload NXP001 will come first.

It is possible but is it likely?

My money is on next rns is that they've commenced the next studies.

Someones enjoying the quiet days picking stock just above the bid.

Also interesting that TRx released their accounts the same day as Oxilio.

*ahem*….

True that. Certainly didn't have any effect on the MM's prices, and SETs has move the bid up now.

Damned if I know.

Agreed older, fingers crossed there are a few suitable donors in good time.

Always fun to see a large 6m trade go through as unknown. Although I feel its a worked sell.

Interesting to see Oxilio's accounts just released.

They're likely to have around £700k available following their recent £850k placing. They had £137k in the bank at the end of Jan (which shows they spent about £800k on the phase 1 clinical) and debtors owing them £460k which is interesting. So approx £1.4m cash or equivalents.

But then they have £720k due to creditors over the next 12 months (from Jan) which leaves a balance of around £700k free for progressing assets.

They submitted further patents after this one so I don’t know how much the refusal based on claims 11 & 12 on this one affect the latter.

https://patentscope.wipo.int/search/en/detail.jsf?docId=JP344317072&_fid=US339759777

No, the NFX patent was refused in Japan.

The only alternative I see Jiving is that someone signs up to an exclusivity option.

Will be interesting how the Kissei side fairs given the company only has ten days left to appeal the refusal of the Japan patent.